The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

Published:2020-02-01 Issue:2 Volume:180 Page:315
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Kim Myung S.¹,Prasad Vinay¹²³

Affiliation:

1. Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland

2. Department of Public Health and Preventive Medicine, Oregon Health and Science University, Portland

3. Center for Health Care Ethics, Oregon Health and Science University, Portland

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2753422/jamainternal_kim_2019_ld_190049.pdf

Reference6 articles.

1. Epidemiology of rare anaemias in Europe.;Gulbis;Adv Exp Med Biol,2010

2. Assessment of pregabalin postapproval trials and the suggestion of efficacy for new indications: a systematic review.;Federico;JAMA Intern Med,2019

3. Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review.;Mattina;PLoS Biol,2017

4. The prevalence and cost of unapproved uses of top-selling orphan drugs.;Kesselheim;PLoS One,2012

5. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.;Castañeda-Sanabria;Eur J Clin Pharmacol,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement‐targeted therapeutics: Are we there yet, or just getting started?;European Journal of Immunology;2024-09-12

2. Real-world safety profile of eculizumab: an analysis of FDA adverse event reporting system and systematic review of case reports;Expert Opinion on Drug Safety;2024-08-26

3. Complement Membrane Attack Complexes Disrupt Proteostasis to Function as Intracellular Alarmins;2024-06-19

4. Promising therapies for the treatment of myasthenia gravis;Expert Opinion on Pharmacotherapy;2024-03-03

5. Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis;Clinical Trials;2024-01-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3